AM-3301

AM-3301 is a dual-acting anti-inflammatory small molecule that was originally developed by Amalyte Pharmaceuticals and subsequently acquired by Kemin Pharma, a division of Kemin Industries, in 2009. The compound was designed to modulate multiple pathways within the inflammatory cascade, a common strategy for treating chronic inflammatory conditions. Following the acquisition of Amalyte, Kemin integrated AM-3301 into its pharmaceutical portfolio alongside other preclinical and clinical-stage anti-bacterial and anti-viral candidates. However, development of AM-3301 appears to have been discontinued, as it is no longer featured in Kemin's active human health pipeline, which has shifted focus toward nutraceutical and dietary supplement ingredients. Detailed information regarding its specific biological targets and clinical trial results remains proprietary and has not been publicly disclosed in peer-reviewed literature.